All In Biotech

Drug Trial Radar · NCT01478594

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects

Last checked: Nov 19, 2026Latest source record: Jul 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 265 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

265

Actual

Start

Dec 2011

Primary completion

Sep 2013

Study completion Jan 2015

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in combination with mFOLFOX6.

Conditions

  • Colorectal Cancer

Interventions

  • TivozanibDrug

    Capsules for oral administration

  • BevacizumabDrug

    Solution for intravenous infusion

  • mFOLFOX6Drug

    mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed Progression-Free Survival (PFS)Time frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group.

Locations

73 sites in 12 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Research Center

    Gilbert, Arizona

  • Genesis Cancer Center

    Hot Springs, Arizona

  • Arizona Clinical Research Center

    Tucson, Arizona

  • University of California San Diego-Morris Cancer Center

    La Jolla, California

  • UC Irvine Medical Center, Division of Hematology/Oncology

    Orange, California

  • Desert Hematology Oncology Medical Group, Inc.

    Rancho Mirage, California

  • Mountain Blue Cancer Care Center

    Golden, Colorado

  • University of Florida, Davis Cancer Center (VA)

    Gainesville, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Queen's Medical Center

    Honolulu, Hawaii

  • University of Hawaii

    Honolulu, Hawaii

  • Kaiser Foundation Hospitals

    Honolulu, Hawaii

  • Northwestern University

    Chicago, Illinois

  • Illinios Cancer Care

    Peoria, Illinois

  • Investigative Clinical Research of Indiana, LLC

    Indianapolis, Indiana

  • Horizon Oncology Research, Inc.

    Lafayette, Indiana

  • Associates of Oncology Hematology, P.C.

    Rockville, Maryland

  • University of Michigan Health

    Ann Arbor, Michigan

  • NYU Cancer Institute

    New York, New York

  • Alamance Regional Medical Center

    Burlington, North Carolina

  • Tri Country Hematology / Oncology

    Canton, Ohio

  • Signal Point Clinical Research Center, LLC

    Middletown, Ohio

  • Cancer Care Associates

    Tulsa, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • Oncology Hematology of Lehigh Valley

    Bethlehem, Pennsylvania

  • Northern Utah Associates

    Ogden, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Tweed Hospital

    Tweed Heads, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Ballarat Health Services

    Ballarat, Victoria, Australia

  • Cabrini Hospital Malvern

    Malvern, Victoria, Australia

  • Border Medical Oncology

    Wodonga, Victoria, Australia

  • Medizinische Universitat Graz

    Graz, Austria

  • Salzburger Landesklinken

    Salzburg, Austria

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Austria

  • Ziekenhuisnetwerk Antwerpen - AZ Middelheim

    Antwerp, Belgium

  • Imelda VZW

    Bonheiden, Belgium

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.